Despite the great potential of NGF for treating neurodegenerative diseases, its therapeutic administration represents a significant challenge as the protein does not cross the blood-brain barrier, owing to its chemical properties, and thus requires long-term delivery to the brain to have a biological effect. This work describes fabrication of nanostructured PSi films as degradable carriers of NGF for sustained delivery of this sensitive protein. The PSi carriers are specifically tailored to obtain high loading efficacy and continuous release of NGF for a period of four weeks, while preserving its biological activity. The behavior of the NGF-PSi carriers as a NGF delivery system is investigated in vitro by examining their capability to induce neuronal differentiation and outgrowth of PC12 cells and dissociated DRG neurons. Cell viability in the presence of neat and NGF-loaded PSi carriers is evaluated. The bioactivity of NGF released from the PSi carriers is compared to the conventional treatment of repetitive free NGF administrations. PC12 cell differentiation is analyzed and characterized by the measurement of three different morphological parameters of differentiated cells; (i) the number of neurites extracting from the soma (ii) the total neurites' length and (iii) the number of branching points. PC12 cells treated with the NGF-PSi carriers demonstrate a profound differentiation throughout the release period. Furthermore, DRG neuronal cells cultured with the NGF-PSi carriers show an extensive neurite initiation, similar to neurons treated with repetitive free NGF administrations. The studied tunable carriers demonstrate the long-term implants for NGF release with a therapeutic potential for neurodegenerative diseases.
Introduction
NGF is essential for the development and maintenance of neurons in the peripheral nervous system (PNS) 1 and plays a crucial role in the survival and function of basal forebrain cholinergic neurons in the central nervous system (CNS) 2 . Its high pharmacological potential for treating central neurodegenerative diseases, such as Alzheimer's and Parkinson's, has been widely demonstrated, with clinical trials currently in progress 3, 4, 5, 6 . The greatest challenge in the delivery of NGF to the CNS resides in its inability to cross the blood brain barrier (BBB), when systemically administered 7 . Moreover, NGF susceptibility to rapid enzymatic degradation renders its short half-life and significantly limits its therapeutic use 8, 9 . Therefore, there is an unmet challenge to design delivery systems which allow for a prolonged and controlled release of NGF in a safe manner. Various NGF delivery systems, including polymer-based systems, have been studied 10, 11, 12, 13, 14, 15, 16, 17 . The release profiles of these systems were often characterized by a distinct initial burst followed by a slow continuous release, where in the latter stage the release rate was significantly low in comparison to the initial burst 11, 18, 19 . Furthermore, inactivation of the protein by the acidic degradation products of the polymers (e.g., poly(lactic-co-glycolic) acid) or loss of NGF bioactivity during the encapsulation process were observed with this systems 20 . Nanostructured PSi is characterized by several appealing properties, including its high surface area, large porous volume, biocompatibility, and tunable degradability in bodily fluids, predestining it for a promising drug delivery platform 21, 22, 23, 24, 25, 26, 27, 28 . Proper selection of its anodization conditions allows to easily adjust the PSi structural properties (e.g., porosity and pore size) for tailoring drug loading and release kinetics 21, 27 . Moreover, various convenient chemical routes allow to modify the surface of the PSi and by that further tune the dissolution rate of the Si scaffold under physiological conditions and the release rates of the drug 22, 24, 29, 30 . This work focuses on designing a PSi-based delivery system for prolonged controlled release of NGF. The effect of the NGF-PSi carriers on neuronal differentiation and outgrowth is examined using PC12 cells and dissociated DRG neurons. We demonstrate that the loaded NGF has retained its bioactivity by inducing neurite outgrowth and profound differentiation throughout a 1-month release period within a single administration.
In vitro NGF Release from PSiO 2
1. Incubate the NGF-loaded PSiO 2 carriers in 2 mL of 0.01 M PBS containing 1% (w/v) BSA and 0.02% (w/v) sodium azide at 37 °C and under orbital agitation of 100 rpm. 2. Every 2 days collect the solution and replace it with 2 mL of fresh PBS. Freeze the collected release samples in liquid nitrogen and store at -20 °C for further analyses. 3. Use the commercially available NGF ELISA assay to quantify NGF content in the release samples as described in steps 3.1-3.9.
NOTE: When preparing the release samples for ELISA quantification, different dilutions should be performed for different time points along the release period (i.e., earlier time points should be diluted much more than later time points). Moreover, for each release sample, at least two different dilutions should be performed and quantified to ensure reaching the concentrations range of the ELISA kit. 4. Determine NGF concentration in the release samples based on the calibration curve and plot a graph of accumulative NGF release over time. NOTE: Higher NGF concentrations (>50 ng/mL) possess the exact effect as the specified concentration. 9. Renew the differentiation medium every 2 days. 10. To evaluate cell viability, add 10% (v/v) of the viability indicator solution (resazurin-based) at representative time points and incubate for 5 h at 37 °C; measure the absorbance at 490 nm using a spectrophotometer.
Quantification of in vitro
2. Mice Dorsal Root Ganglia (DRG) Cell Culture 1. To isolate DRGs from two 7-week-old C57bl mice, first douse the mice with 70% ethanol and make an incision to remove the skin. 2. Cut the base of the skull and the abdominal wall muscles till the spinal cord is exposed. 
Representative Results
Oxidized PSi films are fabricated as described in the protocol. The Si wafer is subjected to electrochemical etching for 20 s at 250 mA/cm The PSiO 2 films are loaded with the NGF loading solution as illustrated in Figure 1aiii . NGF loading is quantified using NGF ELISA by measuring the NGF concentrations in the loading solution before and after incubation with the PSiO 2 films. The average mass of the loaded NGF per PSiO 2 film is determined as 2.8 ± 0.2 µg, which corresponds to a high loading efficacy of 90% (w/w) (data not shown 31 ). In order to establish the NGF release profile from the PSiO 2 carriers, the loaded films are incubated in PBS at 37 °C and every 2 days aliquots are sampled for quantification of the released protein concentration using NGF ELISA. In addition, the Si content in the release samples is quantified using ICP-AES and the Si erosion kinetics of the PSiO 2 carriers is established. Figure 2 depicts the NGF release and the corresponding Si degradation profiles of the porous carriers. A sustained release of NGF, without burst effect, is attained for a period of 1 month. NGF release in the first week is faster (slope = 0.442) compared to a much slower release in later days along the release period (slope 0.043). It should be noted that throughout the entire 1-month release period, the amount of NGF released is sufficient for inducing profound differentiation of PC12 cells, as will be discussed later. The accumulative NGF released is found to be in a good correlation (R 2 = 0.971) with the remaining Si content, as shown in the inset of Figure 2 .
Next, the bioactivity of the NGF-loaded PSiO 2 carriers is characterized in vitro, PC12 cells and DRG neurons are used as models for neuronal differentiation and outgrowth. PC12 cells and dissociated DRG neurons are seeded as described in the protocol. First, cell viability in the presence of the PSiO 2 carriers is examined by incubating the cells with neat (not loaded) or NGF-loaded PSiO 2 ; control plates and cells treated with neat PSiO 2 are supplemented with free NGF every 2 days. No cytotoxicity is observed upon exposure of the cells to the neat or NGFloaded PSiO 2 carriers (Figure 3a) , demonstrating that PSiO 2 is biocompatible with this cell line. (Figure 3e) show an extensive neurite initiation and elongation, similar to the positive control (i.e., neurons supplemented with free NGF, see Figure 3d ), while the negative control (i.e., untreated neurons, see Figure 3c ), exhibits a poor extent of neurite outgrowth.
To evaluate PC12 cells differentiation percentage in the presence of NGF released from the PSiO 2 carriers, differentiation is quantified by counting the cells with neurite outgrowth out of the total cell population. Figure 4 summarizes the results in terms of the percentage of differentiated cells at different time points over a 26-day period. Significant differentiation percentage values are attained throughout the studied duration. Notably, after 26 days, the released NGF has induced differentiation of above 50%, a differentiation percentage which is significantly higher compared to previous studies with polymer-based carriers 16 . These results indicate that NGF entrapment within the porous host preserved the biological activity of the protein for inducing profound differentiation for a period of ~1 month.
To further examine the effect of NGF-PSiO 2 carriers on neuronal differentiation, three characteristic morphological parameters of the differentiated PC12 cells are measured at the single cell level: (i) the number of neurites extracting from the soma (ii) the total neurites' length and (iii) the number of branching points. The cells are treated with NGF-loaded PSiO 2 carriers or with repetitive administration of free NGF (every 2 days), as a control. Figure 5a -c presents the morphometric analysis of the cell population at days 1 and 3. The PC12 cells treated with the NGF-loaded PSiO 2 show morphometric values which are similar to the control treatment for all three tested parameters. After 3 days, the values of all morphological parameters are observed to increase at the same rate for both the NGF-loaded PSiO 2 carriers and the control treatment of repetitive administration of free NGF. 
Discussion
Degradable nanostructured PSiO 2 films are fabricated and employed as carriers for NGF, allowing for its continuous and prolonged release, whilst retaining its biological activity. The potential of the PSiO 2 to serve as a delivery system for NGF is demonstrated in vitro by demonstrating their ability to release sufficient NGF dosage to induce neuronal differentiation and promote outgrowth of PC12 cells and DRG neurons. The engineered films can be used as long-term reservoirs of NGF for future treatment in vivo.
The structural properties of the fabricated PSi films were tailored specifically for NGF payload; the current density of the electrochemical etching process was adjusted to obtain pore size of approximately 40 nm that would easily accommodate the NGF, a protein with a molecular weight of 26.5 kDa 32 and a characteristic diameter of ~4 nm 33 , within the porous matrix. Moreover, thermal oxidation of the porous scaffold was performed to enable physical adsorption of NGF by electrostatic attraction of the positively charged protein to the negatively charged oxidized PSi surface. The surface chemistry of PSi exerts a major effect on the loading efficacy and can be easily tuned in order to better control the interactions between the payload and the porous matrix. These interactions subsequently dictate the structure of adsorbed protein molecules and their bioactivity 34, 35, 36 . The erosion and subsequent dissolution rate are affected by the implantation site, its pathology and disease state 28, 38, 39 . It was established in previous work that if a different release rate is required for a certain therapeutic application, the release profile can be modified and prolonged by changing the surface chemistry of the PSi surface 38, 40, 41 . Various chemical modifications, such as thermal oxidation, thermal carbonization and hydrosilylation techniques, have been shown to stabilize the PSi surface and affect its degradation and consequent payload release 35, 42, 43, 44, 45 . Moreover, loading of NGF into the carriers by covalent attachment of the protein molecules to the Si scaffold via various surface chemistry routes should result in a more prolonged release because the payload is only released when the covalent bonds are broken or the supporting Si matrix is degraded 21 . Furthermore, following its fabrication process, PSi can be rendered into various configurations besides thin films, such as microparticles 46 , nanoparticles 47 or free-standing membranes 26 , which can also be employed as carriers for NGF and meet specific application needs.
In order to be clinically relevant, the NGF content within the PSiO 2 carriers should reach the range of therapeutic doses. In the method described in the protocol, the NGF-loaded PSiO 2 carriers are introduced into a consistent volume of 2 mL of cell media or PBS buffer and thus, the concentration of the loading solution and the respective NGF mass loaded were adjusted to yield a released NGF concentration that is relevant for the tested in vitro system. When utilizing this method for different systems, such as ex vivo or in vivo environments, the concentration of the NGF loading solution should be increased and adjusted according to the needed dose. Alternatively, higher NGF content can be obtained by introducing multiple carriers per tested area or by using larger areas of PSiO 2 samples.
Moreover, it should be noted that in later time points along the release period, the released NGF concentrations are much lower than in earlier time points. The fact that the NGF flux is not constant over time must be taken into consideration when designing the system according to application needs.
Numerous NGF delivery systems have been developed and reported in the literature, most of them are polymer-based systems, comprising of synthetic or natural polymer conjugates 10, 11, 12, 15, 16, 17 . These systems have shown effective sustained release profiles, however, the release period spanned over a period of several days with a significant burst effect. Some of these delivery platforms suffer from critical limitations such as loss of bioactivity upon the encapsulation process, requiring usage of different stabilizing agents 18, 48 , as well as sophisticated and complex fabrication techniques 16 . One of the greatest challenges in designing delivery systems for proteins is the ability to preserve the bioactivity of the molecules upon entrapment within the carrier system. Proteins or peptides can be loaded into PSi/PSiO 2 at RT or even at lower temperatures without using strong organic solvents, which are both important factors when loading these sensitive biomolecules. Previous studies have demonstrated that PSi/PSiO 2 surface chemistry plays a crucial role in minimizing possible denaturation of the loaded proteins 35, 36 . Therefore, PSi/PSiO 2 is an advantageous nanomaterial for developing delivery systems for growth factors in general and NGF in particular.
The current work is focused on utilizing this method as a new therapeutic approach for direct administration of NGF into the CNS for potential treatment of neurodegenerative diseases. The NGF-loaded PSiO 2 carriers can be implanted in mice brains and the efficacy of the platform as long-term implants is studied in vivo. Furthermore, combining this promising carriers with non-invasive biolistics 49, 50 may enable one to administer the NGF-loaded PSiO 2 particles in a highly spatial resolution to a localized area using a novel pneumatic capillary gun for treating neurodegenerative disorders, where a spatiotemporal drug administration is required. Moreover, NGF can direct neuronal growth in a chemical gradient manner 51 , similar to axon guidance molecules. Thus, the loaded PSiO 2 carriers can serve as attractant hot spots to NGF, to direct growth, complementary to other directing cues 52, 53 . In addition, the PSiO 2 carriers can be specifically tailored to sustain the delivery of NGF for a much-extended time period of up to several months by further tuning the PSiO 2 nanostructure and its surface chemistry.
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